Logo Logo
Switch Language to German

Lange, T.; Ernst, T.; Gruber, F.; Maier, J.; Cross, M.; Müller, M. C.; Niederwieser, D. W.; Hochhaus, A. and Pfirrmann, Markus (2013): The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia. In: Haematologica, Vol. 98, No. 5: pp. 714-717

Full text not available from 'Open Access LMU'.

Actions (login required)

View Item View Item